Verrica Pharmaceuticals Faces Nasdaq Delisting Warning
Ticker: VRCA · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting-warning, board-changes, compliance
Related Tickers: VRCA
TL;DR
Nasdaq says Verrica's stock price is too low, giving them until March 31, 2025, to fix it. New directors appointed.
AI Summary
Verrica Pharmaceuticals Inc. announced on October 2, 2024, that it received a notice from The Nasdaq Stock Market LLC regarding its failure to meet the minimum bid price requirement for continued listing. The company has 180 days, until March 31, 2025, to regain compliance. Additionally, the filing details the departure of Director Dr. Paul L. Berns and the election of new directors, including Dr. David J. Stark and Mr. David M. S. Johnson, effective October 2, 2024.
Why It Matters
This filing indicates potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company is at high risk due to receiving a delisting notice from Nasdaq for failing to meet the minimum bid price requirement.
Key Numbers
- 180 days — Compliance Period (Time Verrica has to regain Nasdaq's minimum bid price requirement.)
- March 31, 2025 — Compliance Deadline (The final date Verrica must meet the minimum bid price requirement.)
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- The Nasdaq Stock Market LLC (company) — Listing Market
- October 2, 2024 (date) — Date of earliest event reported
- March 31, 2025 (date) — Deadline to regain compliance
- Dr. Paul L. Berns (person) — Departing Director
- Dr. David J. Stark (person) — Newly Elected Director
- Mr. David M. S. Johnson (person) — Newly Elected Director
FAQ
What specific rule did Verrica Pharmaceuticals fail to satisfy for continued listing on Nasdaq?
Verrica Pharmaceuticals failed to satisfy the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC.
What is the deadline for Verrica Pharmaceuticals to regain compliance with Nasdaq's listing rules?
Verrica Pharmaceuticals has until March 31, 2025, to regain compliance with the minimum bid price requirement.
Who has departed from Verrica Pharmaceuticals' board of directors?
Dr. Paul L. Berns has departed from Verrica Pharmaceuticals' board of directors.
Who were elected as new directors to Verrica Pharmaceuticals' board?
Dr. David J. Stark and Mr. David M. S. Johnson were elected as new directors to Verrica Pharmaceuticals' board.
When were the changes in directors and the Nasdaq notice effective?
The changes in directors and the Nasdaq notice were effective as of October 2, 2024.
Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-10-08 16:16:01
Filing Documents
- d796842d8k.htm (8-K) — 24KB
- 0001193125-24-234391.txt ( ) — 143KB
- vrca-20241002.xsd (EX-101.SCH) — 3KB
- vrca-20241002_lab.xml (EX-101.LAB) — 18KB
- vrca-20241002_pre.xml (EX-101.PRE) — 11KB
- d796842d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: October 8, 2024 /s/ Ted White Ted White President and Chief Executive Officer